stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) Price to free cash flow
Roivant Sciences Ltd. has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 21 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ROIV Roivant Sciences Ltd. | n/m |
| GMAB Genmab A/S Sponsored ADR compare | n/m |
| BNTX BioNTech SE Sponsored ADR compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| INSM Insmed, Inc. compare | n/m |
| RPRX Royalty Pharma PLC compare | 23.3× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 26.1× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 30.4× |
| INCY Incyte Corporation compare | 35.3× |
| Biotechnology industry median | 24.8× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement